• Login
    View Item 
    •   ResearchSpace Home
    • College of Law and Management Studies
    • School of Management, IT and Governance
    • Management
    • Masters Degrees (Management)
    • View Item
    •   ResearchSpace Home
    • College of Law and Management Studies
    • School of Management, IT and Governance
    • Management
    • Masters Degrees (Management)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    The potential for cost savings by extensively using generics for chronic conditions in South Africa.

    Thumbnail
    View/Open
    Nicolosi_Elizabeth_2006.pdf (7.202Mb)
    Date
    2006
    Author
    Nicolosi, Elizabeth.
    Metadata
    Show full item record
    Abstract
    Economic factors are a major constraint to quality health care in Africa. One of the aims of the Department of Health in South Africa is to increase availability and affordability of medicine. One way of reducing the cost of drugs is by introducing legislation to control the price of drugs and by the promotion of generics (interchangeable multisource medicines which are cheaper copies of the original brand name drug). Protocols for the Prescribed Minimum Benefits (PMBs) for the 27 conditions on the Chronic Disease List as published in the Government Gazette in 2003, were legally binding from 1 January 2004 and these conditions must be covered by all medical schemes. Medication prescribed for these conditions may have one or more generic substitutes and Government has allowed certain measures to be introduced by the medical schemes in order to contain costs. This study investigates the potential savings if generics are extensively used for these chronic conditions. A census was conducted on the 25 chronic diseases for which algorithms are available. The empirical quantitative data collected was calculated to quantify potential costs savings in respect of each algorithm. The major findings show that there are large cost differentials between originator drugs and their generic equivalents (97% in the case of prednisone) and smaller cost differentials between generics themselves (54.6% in the case of formoterol). This study also shows that there is a correlation between the number of generic equivalents an originator drug has and the percentage cost differential. A total of 67.5% of all cost differentials between originator and generics are greater than the Department of Health's proposed 40% benchmark pricing. The results support the recommendations that government needs to implement various measures to encourage increased use of generics in this country and to look at realistic benchmark price controls.
    URI
    http://hdl.handle.net/10413/1251
    Collections
    • Masters Degrees (Management) [475]

    DSpace software copyright © 2002-2013  Duraspace
    Contact Us | Send Feedback
    Theme by 
    @mire NV
     

     

    Browse

    All of ResearchSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsAdvisorsTypeThis CollectionBy Issue DateAuthorsTitlesSubjectsAdvisorsType

    My Account

    LoginRegister

    DSpace software copyright © 2002-2013  Duraspace
    Contact Us | Send Feedback
    Theme by 
    @mire NV